Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study

Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around the world, it is extremely important to address the issue of indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well as the scope and regimens of treatment. The article presents the results of our own study, considers the problems of toxicity and tolerability of dose-dense and standard NACT regimens.Aim. To study the tolerability of dose-dense and standard NACT regimens.Materials and methods. The prospective study included 109 patients. 53 patients received dose-dense NACT as preoperative treatment, 56 – the standard NACT regimen.Results. In dose-dense NACT, the frequency and severity of anemia (p = 0.038), hepatotoxicity (p 0.001), peripheral polyneuropathy (p 0.001) increased, but the frequency of delayed start of the cycle in general (p = 0.012) and delay due to neutropenia (p 0.001) decreased.Conclusion. When planning preventive chemotherapy in the treatment of breast cancer (NACT or adjuvant chemotherapy), it is necessary to take into account not only the oncological results in increasing recurrence-free and overall survival, but also the tolerability of therapy.